In a significant ruling on November 16, 2026, the U.S. District Court for the District of Massachusetts granted Alexion Pharmaceuticals’ motion for judgment on the pleadings in a high-profile antitrust suit concerning its blockbuster drug Soliris. The court dismissed claims brought by EmblemHealth, a health insurer and indirect purchaser, which alleged that Alexion unlawfully maintained its monopoly by enforcing patents obtained through fraud to delay biosimilar competition.
Alexion developed eculizumab, marketed as Soliris, securing an initial patent in 2002. Following FDA approval in 2007, the company obtained five additional patents between 2017 and 2020, with expiration dates set for 2027. EmblemHealth contended that these later patents were procured through material misrepresentations and omissions to the U.S. Patent and Trademark Office (USPTO).
The dispute intensified when Samsung Bioepis began developing a biosimilar to Soliris in 2018 and challenged Alexion’s later patents via inter partes review (IPR) proceedings in 2023. The Patent Trial and Appeal Board (PTAB) instituted review after finding a reasonable likelihood that Samsung would prevail on invalidity grounds for each patent challenged. In response, Alexion filed a patent infringement lawsuit against Samsung in January 2024, though the court denied Alexion’s request for injunctive relief.
Following FDA approval of Samsung’s biosimilar, the parties reached a settlement in August 2024, leading to dismissal of both the infringement litigation and the patent challenges. Samsung launched its biosimilar product in April 2025. Separately, Amgen also settled its patent disputes with Alexion and introduced its biosimilar in March 2025.
EmblemHealth filed a putative class action in April 2025, later amending the complaint in June to assert claims of monopolization and attempted monopolization under Section 2 of the Sherman Act, alongside state antitrust, consumer protection, and unjust enrichment claims. The insurer alleged that Alexion’s enforcement of allegedly fraudulently obtained patents unlawfully delayed biosimilar entry beginning in March 2022, causing inflated drug prices for payers.
In December 2025, the district court partially granted Alexion’s motion to dismiss, ruling that EmblemHealth lacked antitrust standing to pursue claims based on the Walker Process exception to Noerr-Pennington immunity. However, the court allowed claims based on the sham litigation exception to proceed. Subsequent motions for reconsideration and interlocutory appeal certification by EmblemHealth were denied.
Alexion moved for judgment on the pleadings in September 2026, with oral arguments held in October. The court’s final ruling dismissed the remaining claims, holding that EmblemHealth failed to establish sham litigation.
Under the Noerr-Pennington doctrine, parties enforcing intellectual property rights through litigation generally enjoy immunity from antitrust liability. Exceptions include cases where patents were procured by fraud on the USPTO (Walker Process) or where litigation is a sham—objectively baseless and used as an anticompetitive tool.
The court reaffirmed that EmblemHealth lacked antitrust standing because its injuries as an indirect purchaser were too remote from the alleged patent fraud, applying the six-factor Associated General Contractors (AGC) test. Furthermore, the court found that Alexion’s favorable settlement with Samsung Bioepis strongly indicated that its infringement lawsuit was not objectively baseless. EmblemHealth’s allegations to the contrary were deemed speculative and insufficient to overcome Noerr-Pennington immunity.
This ruling underscores the high bar for overcoming antitrust immunity in patent enforcement litigation, particularly where settlements with biosimilar challengers demonstrate the reasonableness of patent claims. It also highlights the challenges indirect purchasers face in establishing antitrust standing when their injuries are attenuated from the alleged misconduct.
Case: EmblemHealth, Inc. v. Alexion Pharmaceuticals, Inc., No. 1:25-cv-10985-BEM (D. Mass. Nov. 16, 2026).
Alexion Secures Victory in Massachusetts Antitrust Case Over Soliris Patent Enforcement A federal district court in Massachusetts granted judgment on the pleadings in favor of Alexion Pharmaceuticals, dismissing a putative class action accusing the company of anticompetitive conduct by enforcing allegedly... Read the full IIPLA article: https://iipla.org/news/alexion-secures-victory-in-massachusetts-antitrust-case-over-soliris-patent-enforcement